PI3K Phosphoinositide 3-kinases

Inhibitors

Cat.No.	Name	Information
M2050	GSK2636771	GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor.
M1925	LY294002	LY294002 is a highly selective PI3K inhibitor with IC50 values of 0.31, 0.73, 1.06 and 6.60 μM for PI3Kβ, PI3Kα, PI3Kδ and PI3Kγ respectively.
M2296	3-Methyladenine (3-MA)	3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM, respectively.
M1715	GDC-0941 (Pictilisib)	GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM.
M1984	PF-04691502	PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively.
M21296	PF-06843195	PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts.The Ki of PF-06843195 acting on PI3Kα and PI3Kδ is less than 0.018 nM and 0.28 nM, respectively.PF-06843195 has a significant inhibitory effect on PI3K/mTOR signaling pathway and had a long-lasting anti-tumor effect.
M21171	AZD8154	AZD8154 is a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory diseases.
M21093	NVP-CLR457	NVP-CLR457 is an orally administered, non-CNS-penetrating, pan-IA-like phosphoinositide 3-kinase (PI3K) inhibitor.NVP-CLR457 shows a significant dose-dependent PK / PD / efficacy relationship.NVP-CLR457 has antitumor activity.
M20796	ME-401	ME-401 (PWT-143, P110δ-IN-1) is an oral, potent and selective inhibitor of Phosphatidylinositol 3-Kinase (PI3K) P110δ with IC50 of 0.6 nM in cellular assay.
M20759	3-Hydroxyanthranilic acid	3-Hydroxyanthranilic Acid (3-HAA, 3-HANA), a tryptophan metabolite, has an immunomodulatory effect that may result from inhibition of PI3K/Akt/mTOR and NF-κB activity, thereby decreasing the production of pro-inflammatory mediators.
M20632	Selective PI3Kδ Inhibitor 1 (compound 7n)	Selective PI3Kδ Inhibitor 1 (compound 7n) is an inhibitor of PI3Kδ with an IC50 of 0.9 nM and >1000-fold selectivity against other class I PI3K isoforms [PI3K α/γ/β=3670/1460/21300 nM].
M20610	AMG319	AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
M20589	KDU691	KDU691 is a Plasmodium PI4K -specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively.
M20587	BQR695	BQR695 is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM).
M20353	WAY-278705	WAY-278705 is a phosphoinositide 3-kinase (PI3 kinase) modulator.
M20344	WAY-299017	WAY-299017 is a selective inhibitor of mutant H1047R phosphoinositide- 3-kinase (PI3Ka).
M20331	WAY-232261	WAY-232261 is a PI3 kinase inhibitor.
M20260	WAY-647361	WAY-647361 is a PI3 kinase inhibitor
M20185	WAY-601035	WAY-601035 is a PI3Kγ inhibitor
M20184	WAY-601017	WAY-601017 is a phosphatidylinositol 3-kinase inhibitor
M20049	WAY-272324	WAY-272324 is a Phosphoinositide 3-Kinase γ inhibitor.
M20026	WAY-107407	WAY-107407 altering the lifespan of a eukaryotic organism
M14860	PI4KIIIbeta-IN-9	PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively.
M14859	Vps34-IN-2	Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC₅₀s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively.
M14858	Umbralisib hydrochloride	Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel PI3Kδ inhibitor, with IC₅₀ and EC₅₀ of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against CK1ε, with an EC₅₀ value of 6.0 μM.

Signaling Pathways

Product Type

PI3K Phosphoinositide 3-kinases

Get to Know Us

Customer Support

Resources

Contact Us